Receptor | Configuration | Potentiation by Allopregnanolone | Fractional GABA Response | No of Cells |
---|---|---|---|---|
αβγ | GS/GS | 2.9 ± 0.5 | 0.26 ± 0.03 | 7 |
βαγ-βα | GS/GS | 4.2 ± 1.6 | 0.22 ± 0.09 | 5 |
βαγ-β*α | GS/–S | 10.4 ± 2.6 | 0.23 ± 0.03 | 5 |
βαγ-βα* | GS/G– | 2.2 ± 0.3 | 0.27 ± 0.05 | 4 |
βαγ-β*α* | GS/– – | 4.4 ± 0.5 | 0.23 ± 0.04 | 5 |
βα*γ-βα | G–/GS | 3.4 ± 0.6 | 0.19 ± 0.04 | 4 |
βα*γ-β*α | G–/–S | 2.7 ± 0.3 | 0.28 ± 0.05 | 5 |
βα*γ-βα* | G–/G– | 1.0 ± 0.1 | 0.24 ± 0.15 | 4 |
βα*γ-β*α* | G–/– – | 1.2 ± 0.2 | 0.27 ± 0.01 | 4 |
β*αγ-βα | –S/GS | 4.9 ± 0.6 | 0.21 ± 0.05 | 5 |
β*αγ-β*α | –S/–S | N.D. | N.D. | N.D. |
β*αγ-βα* | –S/G– | 2.5 ± 0.6 | 0.29 ± 0.04 | 6 |
β*αγ-β*α* | –S/– – | N.D. | N.D. | N.D. |
β*α*γ-βα | – –/GS | 4.2 ± 2.0 | 0.26 ± 0.08 | 3 |
β*α*γ-β*α | – –/–S | N.D. | N.D. | N.D. |
β*α*γ-βα* | – –/G– | 1.1 ± 0.1 | 0.26 ± 0.03 | 4 |
β*α*γ-β*α* | – –/– – | N.D. | N.D. | N.D. |
β*, β(Y205S); α*, α(Q241L); G, intact GABA site; S, intact steroid site; N.D., not determined.